T. Rowe Price discloses 13.5% stake in Biolife Solutions
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 6,506,346 shares of Biolife Solutions Inc. common stock, representing 13.5% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 6,506,346 shares of Biolife Solutions Inc. common stock, representing 13.5% of the class. The filing is a Schedule 13G/A amendment signed on 05/15/2026 and states voting and dispositive power is sole for all reported shares.
Insights
Large passive stake disclosed by a major asset manager.
T. Rowe Price Investment Management reports 6,506,346 shares, holding 13.5% of the class. The filing characterizes the position as held in advisory capacity with sole voting and dispositive power for the reported shares.
Future trading activity depends on the firm's client mandates; the filing notes a named fund holds 2,562,102 shares (5.3%). Subsequent filings would show any material changes in percentage or holdings.
Disclosure aligns with Schedule 13G/A reporting for significant holders.
The amendment identifies the filer, CUSIP 09062W204, and supplies itemized voting/dispositive counts. It includes the customary advisor disclaimer denying beneficial ownership while identifying client-level ownership.
Watch for additional amendments if holdings cross regulatory thresholds or if any client accumulates >5% individually.
Key Figures
Key Terms
Schedule 13G/A regulatory
Beneficially owned regulatory
Sole Dispositive Power regulatory
Investment adviser disclaimer regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does T. Rowe Price report in BLFS?
Is the 13.5% stake held on behalf of a specific T. Rowe Price fund?
When was the Schedule 13G/A amendment for BLFS signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.